此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) (PROTECT-CS)

2026年5月29日 更新者：China National Center for Cardiovascular Diseases

Perioperative Recombinant Human Brain Natriuretic Peptide for Renal Protection in Cardiac Surgery: the PROTECT-CS Randomized Clinical Trial

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common and serious perioperative complication, independently associated with prolonged hospitalization, increased mortality, and progression to chronic kidney disease. Despite advances in surgical techniques and postoperative care, no widely accepted pharmacological prevention strategy exists.

Recombinant human brain natriuretic peptide (rhBNP) exerts vasodilatory, diuretic, and natriuretic effects, reduces cardiac preload and afterload, and has demonstrated safety and efficacy in treating congestive heart failure. Preliminary studies suggest rhBNP may reduce postoperative serum creatinine, increase urine output, and improve renal outcomes; however, large-scale randomized controlled evidence is lacking.

The PROTECT-CS trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of perioperative continuous intravenous rhBNP infusion (0.01 μg/kg/min for 48 ± 2 hours) for prevention of AKI in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. A total of 694 participants will be enrolled across 7 centers in China.

研究概览

地位

尚未招聘

条件

干预/治疗

详细说明

Acute kidney injury (AKI) is one of the most common and serious complications following cardiac surgery. CSA-AKI is independently associated with short-term adverse outcomes including prolonged ICU stay, increased need for renal replacement therapy, and in-hospital mortality, as well as long-term consequences including progression to chronic kidney disease and elevated cardiovascular mortality. Despite extensive research efforts, current clinical management of CSA-AKI remains largely supportive, and no pharmacological intervention has been established as a standard preventive strategy in international guidelines.

Recombinant human brain natriuretic peptide (rhBNP, generic name: nesiritide) shares structural and biological activity highly similar to endogenous BNP. Its pharmacological properties include arterial and venous vasodilation, promotion of natriuresis and diuresis, reduction of cardiac preload and afterload, and direct improvement of glomerular filtration rate without adversely affecting serum potassium or creatinine. rhBNP has been widely used in Chinese cardiac surgery and critical care centers for perioperative hemodynamic optimization. Published small-sample randomized trials and a recent meta-analysis have suggested potential renal protective benefits of perioperative rhBNP in cardiac surgery patients; however, these studies were limited by small sample sizes, heterogeneous populations, and the use of renal endpoints as exploratory rather than primary outcomes.

The PROTECT-CS trial aims to address this evidence gap. Eligible participants are adults aged ≥18 years scheduled for elective cardiac surgery under cardiopulmonary bypass who have at least one AKI risk factor (age ≥70 years, preoperative renal impairment, type 2 diabetes mellitus, or heart failure). Participants will be randomized 1:1 using a central IWRS system, stratified by study center with a block size of 6, to receive either continuous intravenous rhBNP at 0.01 μg/kg/min or an equivalent volume of normal saline (placebo), initiated from anesthetic induction to the onset of cardiopulmonary bypass and continued for 48 ± 2 hours total. All participants receive standard perioperative care throughout.

The primary endpoint is the incidence of AKI diagnosed per KDIGO criteria within 7 days postoperatively. Secondary endpoints include AKI incidence within 72 hours, AKI duration and severity, need for renal replacement therapy during hospitalization, changes in renal function biomarkers, hemodynamic parameters, diuretic and vasoactive drug use, major adverse kidney events at 30 and 90 days (MAKE-30 and MAKE-90), 30-day all-cause mortality, ICU and hospital length of stay, and total hospitalization costs.

An independent Data Monitoring Committee (DMC) will conduct periodic safety reviews and a pre-planned interim analysis. Adverse drug reactions are graded per NCI-CTCAE Version 5.0. All study data are collected via an electronic data capture (EDC) system and managed in accordance with GCP standards.

研究类型

介入性

注册 (估计的)

694

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名：Heng Zhang, MD
  • 电话号码：+86-10-88322315

学习地点

  • 中国
      • Beijing、中国
        • Fuwai Hospital, Chinese Academy of Medical Sciences
        • 接触：
          • Sheng Liu, MD
          • 电话号码：+86-10-88392313

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age ≥ 18 years
  • Scheduled (elective) cardiac surgery requiring cardiopulmonary bypass
  • Presence of at least one of the following AKI risk factors:
  • Age ≥ 70 years
  • Preoperative renal impairment (eGFR ≤ 60 mL/min/1.73 m² or urine protein ≥ +2 at screening)
  • Type 2 diabetes mellitus
  • Heart failure, defined as NYHA Class II-IV with NT-proBNP ≥ 125 pg/mL at screening; for participants with atrial fibrillation, NT-proBNP ≥ 365 pg/mL is required
  • Able to understand and provide written informed consent, and willing and able to comply with all study protocol requirements

Exclusion Criteria:

  • Cardiogenic shock
  • Severe hypotension (systolic blood pressure ≤ 90 mmHg) at screening
  • Restrictive or obstructive cardiomyopathy, pericarditis, or cardiac tamponade
  • Preoperative chronic kidney disease stage 4 or higher (eGFR < 30 mL/min/1.73 m²), or renal instability as judged by the investigator
  • Known AKI diagnosed per KDIGO criteria within 48 hours prior to surgery
  • Receipt of any form of renal replacement therapy within 30 days prior to surgery
  • Use of ventricular assist device, intra-aortic balloon pump, or any other mechanical cardiac support device within 7 days prior to surgery
  • Chronic hepatic insufficiency (Child-Pugh Class B or C) or hepatic dysfunction (ALT or AST > 2× upper limit of normal [ULN], or total bilirubin > 1.5× ULN)
  • Active hepatitis B (HBsAg positive with HBV-DNA indicating active viral replication), active hepatitis C (HCV antibody positive with HCV-RNA indicating active viral replication), positive syphilis screen, known HIV infection, or positive HIV test
  • Confirmed or treated endocarditis, sepsis, or active infection requiring antibiotic treatment within 30 days prior to surgery
  • Requirement for aortic dissection repair, complex congenital heart surgery, emergency surgery, or life-saving surgery
  • History of malignant tumor, solid tumor, metastatic tumor, or hematological malignancy within the past 5 years
  • Prior organ transplantation or current use of immunosuppressive agents
  • Any condition that may conflict with or contraindicate the use of intravenous vasodilator therapy
  • Prior adverse reaction to nesiritide (recombinant BNP)
  • Participation in any other clinical trial within 30 days prior to surgery
  • Pregnant or breastfeeding women
  • Any other condition that, in the judgment of the investigator, renders the participant unsuitable for study participation

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：预防
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：四人间

武器和干预

参与者组/臂
干预/治疗
实验性的：rhBNP Treatment Group
Participants receive continuous intravenous infusion of recombinant human brain natriuretic peptide (rhBNP) at 0.01 μg/kg/min, initiated from anesthetic induction to the onset of cardiopulmonary bypass, administered continuously for 48 ± 2 hours. All participants receive standard perioperative cardiac surgical care.
药品：Recombinant Human Brain Natriuretic Peptide (rhBNP)
Continuous intravenous infusion of rhBNP at 0.01 μg/kg/min, initiated at anesthetic induction and continued for 48 ± 2 hours. The infusion rate is consistent with the approved dosage range in the drug prescribing information.
安慰剂比较：Placebo Control Group
Participants receive continuous intravenous infusion of normal saline at an equivalent rate and volume, initiated from anesthetic induction to the onset of cardiopulmonary bypass, administered continuously for 48 ± 2 hours. All participants receive standard perioperative cardiac surgical care.
药品：Normal Saline (Placebo)
Continuous intravenous infusion of normal saline at an equivalent volume and rate to the rhBNP arm, initiated at anesthetic induction and continued for 48 ± 2 hours.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Incidence of acute kidney injury (AKI) within 7 days postoperatively, diagnosed per KDIGO criteria
大体时间：Within 7 days after surgery, or until hospital discharge if earlier
AKI defined per KDIGO 2012 criteria as any of: (1) serum creatinine increase ≥ 0.3 mg/dL (≥ 26.5 μmol/L) within 48 hours; (2) serum creatinine increase to ≥ 1.5 times baseline within 7 days; or (3) urine output < 0.5 mL/kg/h for ≥ 6 consecutive hours. If a participant is discharged earlier than postoperative day 7, AKI events occurring in-hospital are recorded.
Within 7 days after surgery, or until hospital discharge if earlier

次要结果测量

结果测量
措施说明
大体时间
Incidence of AKI within 72 hours postoperatively, diagnosed according to KDIGO criteria
大体时间：Within 72 hours after surgery
Within 72 hours after surgery
Duration of AKI by KDIGO criteria
大体时间：Within 7 days after surgery, or until hospital discharge if earlier
Duration of AKI among participants who develop AKI within 7 days postoperatively, recorded in hours from onset to resolution per KDIGO criteria. If a participant is discharged earlier than postoperative day 7, in-hospital AKI events are recorded.
Within 7 days after surgery, or until hospital discharge if earlier
Severity of AKI by KDIGO stage
大体时间：Within 7 days after surgery, or until hospital discharge if earlier
Distribution of participants across KDIGO Stage 1, Stage 2, and Stage 3, based on the maximum stage reached. If a participant is discharged earlier than postoperative day 7, in-hospital AKI events are recorded.
Within 7 days after surgery, or until hospital discharge if earlier
Incidence of any form of renal replacement therapy (RRT) during the index hospitalization
大体时间：During the index hospitalization
Number of participants receiving any form of RRT (intermittent hemodialysis, continuous renal replacement therapy, or peritoneal dialysis) during the surgical hospitalization.
During the index hospitalization
Change in serum creatinine from preoperative baseline
大体时间：6, 24, 48, and 120 hours and 7 days after surgery
Baseline defined as the last preoperative laboratory result.
6, 24, 48, and 120 hours and 7 days after surgery
Change in urinary creatinine from preoperative baseline
大体时间：6, 24, 48, and 120 hours and 7 days after surgery
Baseline defined as the last preoperative laboratory result.
6, 24, 48, and 120 hours and 7 days after surgery
Change in estimated glomerular filtration rate (eGFR) from preoperative baseline
大体时间：6, 24, 48, and 120 hours and 7 days after surgery
Baseline defined as the last preoperative laboratory result.
6, 24, 48, and 120 hours and 7 days after surgery
Change in pulmonary capillary wedge pressure (PCWP) from post-surgical baseline
大体时间：6, 12, 24, and 48 hours after surgery
Baseline defined as the first measurement obtained after completion of surgery.
6, 12, 24, and 48 hours after surgery
Change in central venous pressure (CVP) from post-surgical baseline
大体时间：6, 12, 24, and 48 hours after surgery
Baseline defined as the first measurement obtained after completion of surgery.
6, 12, 24, and 48 hours after surgery
Change in cardiac output (CO) from post-surgical baseline
大体时间：6, 12, 24, and 48 hours after surgery
Baseline defined as the first measurement obtained after completion of surgery.
6, 12, 24, and 48 hours after surgery
Change in cardiac index (CI) from post-surgical baseline
大体时间：6, 12, 24, and 48 hours after surgery
Baseline defined as the first measurement obtained after completion of surgery.
6, 12, 24, and 48 hours after surgery
Total intraoperative and postoperative diuretic dose
大体时间：From anesthetic induction until hospital discharge
Cumulative dose of diuretic agents administered intraoperatively and postoperatively, reported by drug.
From anesthetic induction until hospital discharge
Total intraoperative and postoperative inotrope dose
大体时间：From anesthetic induction until hospital discharge
Cumulative dose of inotropic agents administered intraoperatively and postoperatively, reported by drug.
From anesthetic induction until hospital discharge
Total intraoperative and postoperative vasopressor dose
大体时间：From anesthetic induction until hospital discharge
Cumulative dose of vasopressor agents administered intraoperatively and postoperatively, reported by drug.
From anesthetic induction until hospital discharge
Total intraoperative and postoperative vasodilator dose
大体时间：From anesthetic induction until hospital discharge
Cumulative dose of vasodilator agents administered intraoperatively and postoperatively, reported by drug.
From anesthetic induction until hospital discharge
Major Adverse Kidney Events at 30 days (MAKE-30)
大体时间：30 days after surgery
Composite endpoint defined as the occurrence of any of the following: death from any cause, receipt of renal replacement therapy, or ≥25% decline in eGFR from baseline.
30 days after surgery
Major Adverse Kidney Events at 90 days (MAKE-90)
大体时间：90 days after surgery
Composite endpoint defined as the occurrence of any of the following: death from any cause, receipt of renal replacement therapy, or ≥25% decline in eGFR from baseline.
90 days after surgery
All-cause mortality at 30 days
大体时间：30 days after surgery
30 days after surgery
Total ICU length of stay
大体时间：Postoperative (From ICU admission until ICU discharge, an average of 3 days)
Total ICU length of stay during the index hospitalization, calculated as the difference between ICU exit time and ICU admission time. For participants with multiple ICU admissions, total ICU length of stay is the sum of all individual ICU stays.
Postoperative (From ICU admission until ICU discharge, an average of 3 days)
Postoperative hospital length of stay during the index hospitalization
大体时间：Postoperative (From the day of surgery until hospital discharge, an average of 7 days)
Postoperative hospital length of stay during the index hospitalization, calculated as the number of days from the date of surgery to the date of hospital discharge. Days of hospitalization before surgery are not included.
Postoperative (From the day of surgery until hospital discharge, an average of 7 days)
Total postoperative medical costs during the index hospitalization
大体时间：Postoperative (From the day of surgery until hospital discharge, an average of 7 days)
Total postoperative medical costs during the index hospitalization, calculated as the sum of all itemized hospital charges incurred from the date of surgery to the date of hospital discharge (including but not limited to surgical fees, ICU fees, medications, laboratory tests, imaging, nursing care, and bed fees), extracted from the hospital information system (HIS) billing records. Charges incurred before surgery are not included.
Postoperative (From the day of surgery until hospital discharge, an average of 7 days)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

China National Center for Cardiovascular Diseases

合作者

Guangdong Provincial People's Hospital
Second Xiangya Hospital of Central South University
First Affiliated Hospital of Chongqing Medical University
Yantai Yuhuangding Hospital
The First Affiliated Hospital of Xiamen University
Shenzhen Sun Yat-sen Cardiovascular Hospital

调查人员

  • 首席研究员：Sheng Liu、Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年5月1日

初级完成 (估计的)

2028年1月31日

研究完成 (估计的)

2029年7月31日

研究注册日期

首次提交

2026年5月14日

首先提交符合 QC 标准的

2026年5月29日

首次发布 (实际的)

2026年6月1日

研究记录更新

最后更新发布 (实际的)

2026年6月1日

上次提交的符合 QC 标准的更新

2026年5月29日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 2026-3155

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

De-identified individual participant data (IPD) underlying the results reported in the primary publication will be made available upon reasonable request, after approval by the principal investigator and data access committee, beginning 12 months after publication of the primary results and available for 36 months thereafter. Data will be shared via a secure data transfer platform. Requests should include a methodologically sound proposal and be directed to the principal investigator.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅